Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Year-end report October - December 2021

Curasight A/S (“Curasight” or “the Company”) hereby publishes the Year-end report for the period October 1 – December 31, 2021. The Year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “As we close the books for the financial year 2021, we can look back on an eventful year in Curasight’s history. In 2021 we have accomplished several important milestones including strengthening Curasight’s IP position within diagnostics and therapy with patent approvals in both US and

First day to exercise Catena Media’s warrants (CTM TO1) for subscription of new shares during eighth exercise period

Catena Media plc (Nasdaq Stockholm: CTM)  Catena Media plc (“Catena Media” or “the company”) today announces that the eighth period to subscribe for shares in the company by exercise of warrants (ticker CTM TO1) (“the warrants”) commences today, 24 February 2022, and will run until and including 5 March 2022. During this period, each warrant entitles the holder to subscribe for one (1) new share in the company at a subscription price of SEK 18.90. Payment of subscribed shares can be made in cash or through set-off with the full nominal amount of each hybrid capital security (ticker

Year-End Report, 2021

Calliditas became the first Company to receive accelerated approval in IgA Nephropathy.“The accelerated approval of TARPEYO was for the indication of reduction of proteinuria, which was the endpoint of Part A of the trial, in adult patients with IgA nephropathy with risk of rapid progression, which is characterized as generally UPCR ≥ 1.5 g/g.  It is well established that patients with higher levels of proteinuria have a worse outlook and prognosis as they tend to experience a more rapid decline of their kidney function, as measured by eGFR. These patients are therefore at considerable risk

BEWI – Results for the fourth quarter of 2021

BEWI, a leading provider of packaging, components, and insulation solutions, today reported its results for the fourth quarter of 2021. BEWI recorded net sales of 208.2 million euro for the fourth quarter of 2021, compared to 130.2 million euro for the same quarter last year, corresponding to an increase of 60 per cent, of which 43 percentage points are organic growth driven by higher volumes and sales prices following strong demand. Adjusted EBITDA came in at 26.4 million euro for the quarter, up from EUR 16.4 million for the fourth quarter last year. The company’s upstream segment, RAW,

Mercell reports growth and margin improvement in 2021

· Continued ARR growth to NOK 793 million, +44% year-on-year with organic growth of 18% · Revenue +83% to NOK 199 million in Q4 and +126% to NOK 706 million in 2021 · Reported EBITDA of NOK 59.7 million in Q4 and NOK 105.0 million for 2021 · Earn-out provisions reversed after downward revision of ARR in Cloudia · Adjusted EBITDA of NOK 35.5 million in Q4 and NOK 172.9 million for 2021 · Current focus on enabling continued strong and profitable growth in the existing businesses · Expecting improved EBITDA-margins in 2022, and solid free cash flow from 2022 onwards · On

Jetpak Top Holding AB (publ):Year-end Report 1 January – 31 December 2021

Fourth quarter: 1 October – 31 December 2021   · Total revenue increased by 9,6 % to 275 319 (251 276) TSEK · Organic growth amounted to 8,5 % (3,9 %) · Gross margin amounted to 31,3 % (30,9 %) · Operating profit amounted to 31 698 (27 795) TSEK · Adjusted EBITA amounted to 31 698 (28 503) TSEK · Net income amounted to 22 828 (16 652) TSEK · Basic earnings per share amounted to 1,90 (1,39) SEK · Diluted earnings per share amounted to 1,89 (1,38) SEK · Cash flow from operations amounted to 32 326 (33 082) TSEK · Cash and cash equivalents amounted to 131 666

Signs new lease agreement with Oatly founders' company Aventure in Estea's life science hub in Lund

Estea has signed a new lease agreement with the research-based food company Aventure, started by Oatly's founders, for office and laboratory premises in Estea's life science hub Forskaren in Lund. The agreement is for just under 10 years and means that Aventure doubles its area to 1,400 sqm. Estea has begun extensive adaptations that will provide Aventure with state-of-the-art offices and labs including a pilot hall for food development. - We are pleased to have the continued trust from Aventure. The Forskaren building is strategically located in the heart of Medicon Valley, one of

Lundin Gold Reports Fourth Quarter and Full Year Results

Production and Cost Performance Beats Guidance, Resulting in Free Cash Flow of $268 million Generated in 2021VANCOUVER, BC, February 23, 2022 /CNW/ Lundin Gold Inc. (TSX: LUG; Nasdaq Stockholm: LUG) ("Lundin Gold" or the "Company") today reports results for the fourth quarter and year ended December 31, 2021 (the “2021 Year”).  Lundin Gold’s excellent year is highlighted by its production of 428,514 oz of gold at an All-in Sustaining Cost (AISC)¹ of $762 per oz, beating guidance of 380,000 to 420,000 oz and AISC of $770 to $830 per oz, respectively, and resulting in free cash flow¹ of $268

Orkla Health acquires Healthspan

Orkla Health has acquired 100 per cent of the shares in Healthspan Group Limited, a leading supplier of dietary supplements in the British market.Healthspan was established in 1996 and has since built up a strong brand and a broad range of dietary supplements and skin care products. A total of 92 per cent of the company’s sales are made directly to consumers and the company has around half a million active customers.   “This acquisition is a strategically important purchase for us along several dimensions. It supports our ambitions of establishing a stronger position in consumer

Nordea Bank Abp: Repurchase of own shares on 23.02.2022

Nordea Bank AbpStock exchange release – Changes in company’s own shares23.02.2022 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 23.02.2022 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number of Weighted average Total cost, EUR* **venue (MIC shares price / share, EUR* Code) **XSTO 400,949 10.27 4,116,598.66XHEL 401,391 10.26 4,119,074.44CEUX 370,562 10.26 3,801,377.48AQEU 17,539 10.29

Observe Medical ASA – Preliminary results of the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE. Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 9 February 2022 regarding the commencement of the subscription period in the rights issue of 25,714,286 new

Investor Report

Regulatory Announcement Royal Bank of CanadaFebruary 23, 2022 RBC Covered Bond Programme Monthly Investor Report The RBC Covered Bond Programme Monthly Investor Report has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism To view the full document, please paste the following URL into the address bar of your browser. RBC Covered Bond Programme Monthly Investor Report dated January 31, 2022http://www.rns-pdf.londonstockexchange.com/rns/6257C_1-2022-2-23.pdf A copy of

Toivo Group Plc to begin communications in English

Company release 23 February 2022 7:00 p.m. Toivo Group Plc (“Toivo” or the “Company”) will begin communicating in English in addition to the current Finnish as of 24 February 2022. Toivo will publish its first English business review alongside the Finnish business review in relation to the 2022 first quarter business review on 11 May 2022. The Company will not publish the 2021 annual report and financial statement in English. The Company’s financial statement release 2021 and financial statement release presentation 2021, which were previously published on 18 February 2022, can be read

SRV Group Plc: Repurchase of own shares on 23 February 2022

SRV GROUP PLC     STOCK EXCHANGE RELEASE     23 FEBRUARY 2022      18:45 EET   SRV Group Plc repurchase of own shares on 23.02.2022     +------------------------+----------+|SRV Group Plc |  |+------------------------+----------+|In the Nasdaq Helsinki |  |+------------------------+----------+|Date |23.02.2022|+------------------------+----------+|Exchange transaction |BUY |+------------------------+----------+|Share trading code |SRV1V |+------------------------+----------+|Amount, shares

Holding(s) in Company

TR-1: Standard form for notification of major holdings   NOTIFICATION OFMAJOR HOLDINGS(tobe sent to therelevant issuerandto the FCA inMicrosoft Wordformatif possible)i 1a. Identity of EnQuest PLCthe issuer or theunderlying issuerof existingsharesto which votingrights areattachedii:1b. Pleaseindicate if theissuer isa non-UK issuer (please markwithan “X” ifappropriate)Non-UK issuer  2. Reason for thenotification(please mark theappropriate boxorboxes with an“

UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 23.02.2022

United Bankers Plc NOTIFICATION 23.02.2022 at 18:30 UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 23.02.2022 Date 23.02.2022Exchange transaction BuyShare class UNITEDAmount 233Average price/share 13.7142 EURHighest price/share 13.8000 EURLowest price/share 13.6000 EURTotal price 3,195.41 EUR The shares held by United Bankers Plc on 23.02.2022: UNITED 61,021 On behalf of United Bankers Plc  Skandinaviska Enskilda Banken AB (Publ) Antti Salakka         Janne Tiihonen For

Repurchase of own shares

TietoEVRY Corporation          STOCK EXCHANGE RELEASE          23 February 2022, 6.30 p.m. EET Date                                            23 February 2022 Exchange transaction              Buy Share class                                TIETO Amount, shares                        46 000 Average price/share                EUR 25.5083 Total price, EUR                        1 173 381.80 The number of shares held by Tietoevry Corporation after the completion of transactions: 131 587 shares. On behalf of TietoEVRY Corporation      EVLI BANK PLC

#22-62 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

#22-61 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

#22-60 Changes to certain Derivatives at NGM

ISIN: CH1114178804 and CH1114178788 from issuer Valour Inc. has changed first trading day to 2022-02-28, in that way this is a correction to the information announced in NGM Notice Financial Markets #22-59.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of

Cosmic flashes pinpointed to a surprising location in space

[Source of mysterious radio signals an artists impression of a magnetar in a cluster of ancient stars in red close to the spiral galaxy Messier 81 M81 ]   Astronomers have been surprised by the closest source of the mysterious flashes in the sky known as fast radio bursts. Precision measurements with radio telescopes reveal that the bursts are made among old stars, and in a way that no one was expecting. The source of the flashes, in nearby spiral galaxy M 81, is the closest of its kind to Earth. Fast radio bursts are unpredictable, extremely short flashes of light from space.

Atea ASA - share buyback

Oslo, 23 February On 23 February 2022, Atea ASA has purchased a total of 38,403 own shares at the Oslo Stock Exchange at an average price of NOK 135.47 per share. Following the completion of the above transactions, Atea ASA owns a total of 347,511 own shares, corresponding to 0.31% of Atea ASA's share capital. Additional information on the buyback program: Date on which the buyback program was announced: 11 February 2022 The duration of the buyback program: 14 February 2022 to 31 March 2022, or until the maximum number of shares has been repurchased. Size of the buyback

Webstep ASA: Mandatory notification of trade by primary insiders and closely related persons

Oslo, 23 February 2022: Reference is made to the stock exchange announcement published by Webstep ASA (the "Company") earlier today, on 23 February 2022, regarding the resolution by the Company's board of directors to increase the Company's share capital with NOK 77,902 by the issuance of 77,902 new shares, each with a par value of NOK 1.00, in order to facilitate the delivery of new shares to the option holders having exercised 77,902 options under the Company's long-term incentive program.The following primary insider of the Company have today, on 23 February 2022, exercised options and

ABS – Board approval of share capital increase related to share option exercises

Reference is made to the stock exchange release published by Arctic Bioscience 22 February 2022 regarding exercise of share options and corresponding issuance of new shares in Arctic Bioscience.On 23 February 2022, the board of Arctic Bioscience, on the basis of a board authorization granted by the general meeting, resolved to increase the share capital from NOK 2,429,953.90, a share capital increase of by NOK 7,618 to NOK 2,437,571.90 by subscription of 76,180 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 9.845 per share, including a share premium of

There are no items matching the current filter
There are no more items matching the current filter
Back to top